Korean J Urol.  2012 Sep;53(9):583-592. 10.4111/kju.2012.53.9.583.

Management of Lower Urinary Tract Dysfunction in Patients with Neurological Disorders

• Li WJ
• Oh SJ

• KMID: 2061695
• DOI: http://doi.org/10.4111/kju.2012.53.9.583

Abstract

The proper performance of the lower urinary tract is dependent on an intact neural innervation of the individual structures involved. Therefore, any congenital neurological anomalies, diseases, or lesions of the central, peripheral, or autonomic nervous systems can result in lower urinary tract symptoms. Lower urinary tract dysfunction (LUTD) secondary to neurological disorders can significantly reduce quality of life (QoL) and may also give rise to serious complications and psychological and social sequelae. The goals of management of LUTD in patients with neurological disorders are to prevent serious complications and to improve the patient's QoL. Understanding the physiology and pathophysiology of micturition is critical to selecting appropriate treatment options. This article provides an overview of the clinical characteristics, diagnosis, and management of LUTD in patients with certain central and peripheral neuropathies and common lesions.

Keyword

Clean intermittent catheterization; Lower urinary tract symptoms; Nervous system diseases; Neurogenic urinary bladder; Urodynamics

MeSH Terms

Autonomic Nervous System
Humans
Intermittent Urethral Catheterization
Lower Urinary Tract Symptoms
Nervous System Diseases
Peripheral Nervous System Diseases
Quality of Life
Urinary Bladder, Neurogenic
Urinary Tract
Urination
Urodynamics

Reference

1. Yoshimura N, de Groat WC. Neural control of the lower urinary tract. Int J Urol. 1997. 4:111–125.

2. de Groat WC. Integrative control of the lower urinary tract: preclinical perspective. Br J Pharmacol. 2006. 147:Suppl 2. S25–S40.

3. Gulur DM, Drake MJ. Management of overactive bladder. Nat Rev Urol. 2010. 7:572–582.

4. Gormley EA. Urologic complications of the neurogenic bladder. Urol Clin North Am. 2010. 37:601–607.

5. Kwon T, Park J, Park MC, Han JY, Kim KS. Risk factors for upper urinary tract deterioration in children with neurogenic bladder. Korean J Urol. 2009. 50:1248–1252.

6. Burney TL, Senapati M, Desai S, Choudhary ST, Badlani GH. Acute cerebrovascular accident and lower urinary tract dysfunction: a prospective correlation of the site of brain injury with urodynamic findings. J Urol. 1996. 156:1748–1750.

7. Kong KH, Young S. Incidence and outcome of poststroke urinary retention: a prospective study. Arch Phys Med Rehabil. 2000. 81:1464–1467.

8. Marinkovic SP, Badlani G. Voiding and sexual dysfunction after cerebrovascular accidents. J Urol. 2001. 165:359–370.

9. Sakakibara R, Hattori T, Yasuda K, Yamanishi T. Micturitional disturbance after acute hemispheric stroke: analysis of the lesion site by CT and MRI. J Neurol Sci. 1996. 137:47–56.

10. Nakayama H, Jorgensen HS, Pedersen PM, Raaschou HO, Olsen TS. Prevalence and risk factors of incontinence after stroke. The Copenhagen Stroke Study. Stroke. 1997. 28:58–62.

11. Swaminath PV, Ragothaman M, Koshy S, Sarangmath N, Adhyam M, Subbakrishna DK, et al. Urogenital symptoms in Parkinson's disease and multiple system atrophy-Parkinsonism: at onset and later. J Assoc Physicians India. 2010. 58:86–90.

12. Campeau L, Soler R, Andersson KE. Bladder dysfunction and parkinsonism: current pathophysiological understanding and management strategies. Curr Urol Rep. 2011. 12:396–403.

13. Wenning GK, Colosimo C, Geser F, Poewe W. Multiple system atrophy. Lancet Neurol. 2004. 3:93–103.

14. Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008. 71:670–676.

15. Köllensperger M, Geser F, Ndayisaba JP, Boesch S, Seppi K, Ostergaard K, et al. Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord. 2010. 25:2604–2612.

16. Fowler CJ, Dalton C, Panicker JN. Review of neurologic diseases for the urologist. Urol Clin North Am. 2010. 37:517–526.

17. Bloch F, Pichon B, Bonnet AM, Pichon J, Vidailhet M, Roze E, et al. Urodynamic analysis in multiple system atrophy: characterisation of detrusor-sphincter dyssynergia. J Neurol. 2010. 257:1986–1991.

18. Uchiyama T, Sakakibara R, Yamamoto T, Ito T, Yamaguchi C, Awa Y, et al. Urinary dysfunction in early and untreated Parkinson's disease. J Neurol Neurosurg Psychiatry. 2011. 82:1382–1386.

19. Araki I, Kitahara M, Oida T, Kuno S. Voiding dysfunction and Parkinsons disease: urodynamic abnormalities and urinary symptoms. J Urol. 2000. 164:1640–1643.

20. Sakakibara R, Hattori T, Uchiyama T, Yamanishi T. Videourodynamic and sphincter motor unit potential analyses in Parkinson's disease and multiple system atrophy. J Neurol Neurosurg Psychiatry. 2001. 71:600–606.

21. Pramstaller PP, Wenning GK, Smith SJ, Beck RO, Quinn NP, Fowler CJ. Nerve conduction studies, skeletal muscle EMG, and sphincter EMG in multiple system atrophy. J Neurol Neurosurg Psychiatry. 1995. 58:618–621.

22. Sakakibara R, Uchiyama T, Yamanishi T, Kishi M. Sphincter EMG as a diagnostic tool in autonomic disorders. Clin Auton Res. 2009. 19:20–31.

23. Cameron AP, Rodriguez GM, Schomer KG. Systematic review of urological followup after spinal cord injury. J Urol. 2012. 187:391–397.

24. Jeong SJ, Cho SY, Oh SJ. Spinal cord/brain injury and the neurogenic bladder. Urol Clin North Am. 2010. 37:537–546.

25. Han SJ, Lee JE. Risk factors for urinary tract infection in chronic spinal cord injured patients. J Korean Acad Rehabil Med. 2005. 29:181–186.

26. Watanabe T, Rivas DA, Chancellor MB. Urodynamics of spinal cord injury. Urol Clin North Am. 1996. 23:459–473.

27. Sahai A, Cortes E, Seth J, Khan MS, Panicker J, Kelleher C, et al. Neurogenic detrusor overactivity in patients with spinal cord injury: evaluation and management. Curr Urol Rep. 2011. 12:404–412.

28. Abrams P, Agarwal M, Drake M, El-Masri W, Fulford S, Reid S, et al. A proposed guideline for the urological management of patients with spinal cord injury. BJU Int. 2008. 101:989–994.

29. Krassioukov A, Warburton DE, Teasell R, Eng JJ. Spinal Cord Injury Rehabilitation Evidence Research Team. A systematic review of the management of autonomic dysreflexia after spinal cord injury. Arch Phys Med Rehabil. 2009. 90:682–695.

30. Rabchevsky AG, Kitzman PH. Latest approaches for the treatment of spasticity and autonomic dysreflexia in chronic spinal cord injury. Neurotherapeutics. 2011. 8:274–282.

31. Mourtzinos A, Stoffel JT. Management goals for the spina bifida neurogenic bladder: a review from infancy to adulthood. Urol Clin North Am. 2010. 37:527–535.

32. de Jong TP, Chrzan R, Klijn AJ, Dik P. Treatment of the neurogenic bladder in spina bifida. Pediatr Nephrol. 2008. 23:889–896.

33. Scales CD Jr, Wiener JS. Evaluating outcomes of enterocystoplasty in patients with spina bifida: a review of the literature. J Urol. 2008. 180:2323–2329.

34. Daneshgari F, Moore C. Diabetic uropathy. Semin Nephrol. 2006. 26:182–185.

35. Gomez CS, Kanagarajah P, Gousse AE. Bladder dysfunction in patients with diabetes. Curr Urol Rep. 2011. 12:419–426.

36. Daneshgari F, Liu G, Birder L, Hanna-Mitchell AT, Chacko S. Diabetic bladder dysfunction: current translational knowledge. J Urol. 2009. 182:6 Suppl. S18–S26.

37. Li WJ, Oh SJ. Diabetic cystopathy is associated with PARP/JNK/mitochondrial apoptotic pathway-mediated bladder apoptosis. Neurourol Urodyn. 2010. 29:1332–1337.

38. Li WJ, Shin MK, Oh SJ. Poly(ADP-ribose) polymerase is involved in the development of diabetic cystopathy via regulation of nuclear factor kappa B. Urology. 2011. 77:1265.e1–1265.e8.

39. Kaplan SA, Te AE, Blaivas JG. Urodynamic findings in patients with diabetic cystopathy. J Urol. 1995. 153:342–344.

40. Bansal R, Agarwal MM, Modi M, Mandal AK, Singh SK. Urodynamic profile of diabetic patients with lower urinary tract symptoms: association of diabetic cystopathy with autonomic and peripheral neuropathy. Urology. 2011. 77:699–705.

41. Dib PT, Trigo-Rocha F, Gomes CM, Srougi M. Urodynamic evaluation in diabetic patients with prostate enlargement and lower urinary tract symptoms. Urol Int. 2008. 80:378–382.

42. Benevento BT, Sipski ML. Neurogenic bladder, neurogenic bowel, and sexual dysfunction in people with spinal cord injury. Phys Ther. 2002. 82:601–612.

43. Ku JH. The management of neurogenic bladder and quality of life in spinal cord injury. BJU Int. 2006. 98:739–745.

44. Oh SJ, Ku JH, Jeon HG, Shin HI, Paik NJ, Yoo T. Health-related quality of life of patients using clean intermittent catheterization for neurogenic bladder secondary to spinal cord injury. Urology. 2005. 65:306–310.

45. Sauerwein D. Urinary tract infection in patients with neurogenic bladder dysfunction. Int J Antimicrob Agents. 2002. 19:592–597.

46. Shin JC, Yoo JH, Park JW, Park S, Ahn SJ, Park CI. Difference of organism and their antibiotics sensitivity from urine culture in symptomatic urinary tract infection of spinal cord injury patients. J Korean Acad Rehabil Med. 2008. 32:38–44.

47. Kelly CE. Evaluation of voiding dysfunction and measurement of bladder volume. Rev Urol. 2004. 6:Suppl 1. S32–S37.

48. Dromerick AW, Edwards DF. Relation of postvoid residual to urinary tract infection during stroke rehabilitation. Arch Phys Med Rehabil. 2003. 84:1369–1372.

49. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002. 21:167–178.

50. Bright E, Drake MJ, Abrams P. Urinary diaries: evidence for the development and validation of diary content, format, and duration. Neurourol Urodyn. 2011. 30:348–352.

51. Bright E, Cotterill N, Drake M, Abrams P. Developing a validated urinary diary: phase 1. Neurourol Urodyn. 2012. 31:625–633.

52. Ku JH, Jeong IG, Lim DJ, Byun SS, Paick JS, Oh SJ. Voiding diary for the evaluation of urinary incontinence and lower urinary tract symptoms: prospective assessment of patient compliance and burden. Neurourol Urodyn. 2004. 23:331–335.

53. McGuire EJ, Woodside JR, Borden TA, Weiss RM. Prognostic value of urodynamic testing in myelodysplastic patients. 1981. J Urol. 2002. 167(2 Pt 2):1049–1053.

54. Bacsu CD, Chan L, Tse V. Diagnosing detrusor sphincter dyssynergia in the neurological patient. BJU Int. 2012. 109:Suppl 3. 31–34.

55. Park JS, Park WH. The analysis of risk factors for upper urinary tract disease in spinal cord injured patients: including video urodynamic findings. Korean J Urol. 2005. 46:943–949.

56. Hyman MJ, Groutz A, Blaivas JG. Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J Urol. 2001. 166:550–552.

57. Wyndaele JJ. Correlation between clinical neurological data and urodynamic function in spinal cord injured patients. Spinal Cord. 1997. 35:213–216.

58. Weld KJ, Dmochowski RR. Association of level of injury and bladder behavior in patients with post-traumatic spinal cord injury. Urology. 2000. 55:490–494.

59. Cameron AP. Pharmacologic therapy for the neurogenic bladder. Urol Clin North Am. 2010. 37:495–506.

60. Dorsher PT, McIntosh PM. Neurogenic bladder. Adv Urol. 2012. 2012:816274.

61. Wyndaele JJ, Kovindha A, Madersbacher H, Radziszewski P, Ruffion A, Schurch B, et al. Neurologic urinary incontinence. Neurourol Urodyn. 2010. 29:159–164.

62. Koch T, Kelly S. Identifying strategies for managing urinary incontinence with women who have multiple sclerosis. J Clin Nurs. 1999. 8:550–559.

63. Winder A. Intermittent self-catheterisation. Nurs Times. 2002. 98:50.

64. Oh SJ, Ku JH, Lim SH, Jeon HG, Son H. Effect of a 'centralized intensive education system' for clean intermittent self-catheterization in patients with voiding dysfunction who start catheterization for the first time. Int J Urol. 2006. 13:905–909.

65. Feifer A, Corcos J. Contemporary role of suprapubic cystostomy in treatment of neuropathic bladder dysfunction in spinal cord injured patients. Neurourol Urodyn. 2008. 27:475–479.

66. Ito T, Sakakibara R, Yasuda K, Yamamoto T, Uchiyama T, Liu Z, et al. Incomplete emptying and urinary retention in multiple-system atrophy: when does it occur and how do we manage it? Mov Disord. 2006. 21:816–823.

67. Katsumi HK, Kalisvaart JF, Ronningen LD, Hovey RM. Urethral versus suprapubic catheter: choosing the best bladder management for male spinal cord injury patients with indwelling catheters. Spinal Cord. 2010. 48:325–329.

68. Kennelly MJ, Devoe WB. Overactive bladder: pharmacologic treatments in the neurogenic population. Rev Urol. 2008. 10:182–191.

69. Stöhrer M, Blok B, Castro-Diaz D, Chartier-Kastler E, Del Popolo G, Kramer G, et al. EAU guidelines on neurogenic lower urinary tract dysfunction. Eur Urol. 2009. 56:81–88.

70. Stöhrer M, Murtz G, Kramer G, Schnabel F, Arnold EP, Wyndaele JJ, et al. Propiverine compared to oxybutynin in neurogenic detrusor overactivity--results of a randomized, double-blind, multicenter clinical study. Eur Urol. 2007. 51:235–242.

71. Amend B, Hennenlotter J, Schafer T, Horstmann M, Stenzl A, Sievert KD. Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. Eur Urol. 2008. 53:1021–1028.

72. Horstmann M, Schaefer T, Aguilar Y, Stenzl A, Sievert KD. Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage. Neurourol Urodyn. 2006. 25:441–445.

73. Bennett N, OLeary M, Patel AS, Xavier M, Erickson JR, Chancellor MB. Can higher doses of oxybutynin improve efficacy in neurogenic bladder? J Urol. 2004. 171(2 Pt 1):749–751.

74. Aslan AR, Kogan BA. Conservative management in neurogenic bladder dysfunction. Curr Opin Urol. 2002. 12:473–477.

75. Wang P, Luthin GR, Ruggieri MR. Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins. J Pharmacol Exp Ther. 1995. 273:959–966.

76. Cartwright PC, Coplen DE, Kogan BA, Volinn W, Finan E, Hoel G. Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity. J Urol. 2009. 182:1548–1554.

77. Kennelly MJ, Lemack GE, Foote JE, Trop CS. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study. Urology. 2009. 74:741–745.

78. Van Meel TD, De Wachter S, Wyndaele JJ. The effect of intravesical oxybutynin on the ice water test and on electrical perception thresholds in patients with neurogenic detrusor overactivity. Neurourol Urodyn. 2010. 29:391–394.

79. Michel MC, Vrydag W. Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol. 2006. 147:Suppl 2. S88–S119.

80. Consortium for Spinal Cord Medicine. Bladder management for adults with spinal cord injury: a clinical practice guideline for health-care providers. J Spinal Cord Med. 2006. 29:527–573.

81. Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2011. 60:742–750.

82. Cruz CD, Cruz F. Spinal cord injury and bladder dysfunction: new ideas about an old problem. ScientificWorldJournal. 2011. 11:214–234.

83. Duthie JB, Vincent M, Herbison GP, Wilson DI, Wilson D. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev. 2011. (12):CD005493.

84. Mangera A, Andersson KE, Apostolidis A, Chapple C, Dasgupta P, Giannantoni A, et al. Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur Urol. 2011. 60:784–795.

85. Stein R, Schroder A, Thuroff JW. Bladder augmentation and urinary diversion in patients with neurogenic bladder: surgical considerations. J Pediatr Urol. 2012. 8:153–161.

86. Wiener JS, Antonelli J, Shea AM, Curtis LH, Schulman KA, Krupski TL, et al. Bladder augmentation versus urinary diversion in patients with spina bifida in the United States. J Urol. 2011. 186:161–165.

87. Biers SM, Venn SN, Greenwell TJ. The past, present and future of augmentation cystoplasty. BJU Int. 2012. 109:1280–1293.

88. Austin JC. Long-term risks of bladder augmentation in pediatric patients. Curr Opin Urol. 2008. 18:408–412.